Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21698646 | 0.97 | CYP11B2 (0.67) | CYP11B2HCAR1 | |
| SCHEMBL21698770 | 0.97 | CYP11B2 (0.70) | CYP11B2 | |
| SCHEMBL23128857 | 0.89 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL23128878 | 0.89 | CYP11B2 (0.64) | CYP11B2 | |
| SCHEMBL21831949 | 0.85 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL21831948 | 0.85 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL21832029 | 0.80 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL21832014 | 0.79 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL21831998 | 0.74 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL21832062 | 0.74 | CYP11B2 (0.80) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| CN-114213421-A | 1H-imidazole [4,5-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-109803972-B | 1H-imidazole [4,5-H ] quinazoline compound as protein kinase inhibitor | 晟科药业（江苏）有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | CYP11B2 3436/4885HCAR1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.